Total Payments
$22,854
2024 Payments
$197.12
Companies
17
Transactions
57
Medicare Patients
2,242
Medicare Billing
$820,932
Payment Breakdown by Category
Other$20,000 (87.5%)
Food & Beverage$1,698 (7.4%)
Consulting$690.00 (3.0%)
Education$289.82 (1.3%)
Travel$176.55 (0.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $20,000 | 9 | 87.5% |
| Food and Beverage | $1,698 | 39 | 7.4% |
| Consulting Fee | $690.00 | 3 | 3.0% |
| Education | $289.82 | 4 | 1.3% |
| Travel and Lodging | $176.55 | 2 | 0.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Millennium Pharmaceuticals, Inc. | $15,399 | 11 | $0 (2017) |
| PFIZER INC. | $2,902 | 3 | $0 (2017) |
| AstraZeneca Pharmaceuticals LP | $2,655 | 7 | $0 (2019) |
| Novartis Pharmaceuticals Corporation | $427.07 | 5 | $0 (2024) |
| COMSORT, Inc | $350.00 | 2 | $0 (2018) |
| E.R. Squibb & Sons, L.L.C. | $257.44 | 4 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $192.37 | 4 | $0 (2024) |
| Astellas Pharma US Inc | $177.95 | 2 | $0 (2020) |
| Myriad Genetic Laboratories, Inc. | $137.86 | 2 | $0 (2023) |
| Genentech USA, Inc. | $101.06 | 8 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $197.12 | 9 | Novartis Pharmaceuticals Corporation ($82.45) |
| 2023 | $189.42 | 4 | Myriad Genetic Laboratories, Inc. ($137.86) |
| 2021 | $11.92 | 1 | Gilead Sciences, Inc. ($11.92) |
| 2020 | $495.48 | 6 | Novartis Pharmaceuticals Corporation ($344.62) |
| 2019 | $125.01 | 1 | AstraZeneca Pharmaceuticals LP ($125.01) |
| 2018 | $657.28 | 11 | COMSORT, Inc ($150.00) |
| 2017 | $21,178 | 25 | Millennium Pharmaceuticals, Inc. ($15,399) |
All Payment Transactions
57 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/31/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $26.57 | General |
| Category: Oncology | ||||||
| 10/31/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $22.83 | General |
| Category: Oncology | ||||||
| 10/16/2024 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI, TUKYSA | Food and Beverage | In-kind items and services | $15.80 | General |
| Category: ONCOLOGY | ||||||
| 10/03/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $23.81 | General |
| Category: Oncology | ||||||
| 09/25/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $13.08 | General |
| Category: Oncology | ||||||
| 09/19/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $22.22 | General |
| Category: ONCOLOGY | ||||||
| 09/18/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Food and Beverage | In-kind items and services | $25.92 | General |
| Category: ONCOLOGY | ||||||
| 05/15/2024 | E.R. Squibb & Sons, L.L.C. | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $14.82 | General |
| Category: Hematology | ||||||
| 01/30/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $32.07 | General |
| Category: Oncology | ||||||
| 11/21/2023 | Myriad Genetic Laboratories, Inc. | MYRISK (Device) | Food and Beverage | In-kind items and services | $118.17 | General |
| Category: ONCOLOGY | ||||||
| 11/21/2023 | Myriad Genetic Laboratories, Inc. | MYRISK (Device) | Food and Beverage | In-kind items and services | $19.69 | General |
| Category: ONCOLOGY | ||||||
| 04/24/2023 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $22.25 | General |
| Category: ONCOLOGY | ||||||
| 03/06/2023 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $29.31 | General |
| Category: ONCOLOGY | ||||||
| 06/01/2021 | Gilead Sciences, Inc. | — | Education | In-kind items and services | $11.92 | General |
| 10/01/2020 | Incyte Corporation | PEMAZYRE (Drug), JAKAFI | Food and Beverage | Cash or cash equivalent | $18.39 | General |
| Category: Hepatology (Liver, Pancreatic, Gall Bladder) | ||||||
| 09/30/2020 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Consulting Fee | Cash or cash equivalent | $340.00 | General |
| Category: ONCOLOGY | ||||||
| 09/30/2020 | Novartis Pharmaceuticals Corporation | MEKINIST (Drug), TAFINLAR | Food and Beverage | In-kind items and services | $4.62 | General |
| Category: ONCOLOGY | ||||||
| 06/03/2020 | Takeda Pharmaceuticals U.S.A., Inc. | ALUNBRIG (Drug) | Food and Beverage | In-kind items and services | $20.09 | General |
| Category: ONCOLOGY | ||||||
| 05/26/2020 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $12.43 | General |
| Category: Oncology | ||||||
| 01/23/2020 | Astellas Pharma US Inc | — | Education | In-kind items and services | $99.95 | General |
| 09/26/2019 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $125.01 | General |
| Category: Oncology | ||||||
| 11/27/2018 | Takeda Pharmaceuticals U.S.A., Inc. | NINLARO (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Oncology | ||||||
| 11/15/2018 | Genentech USA, Inc. | Perjeta (Biological) | Food and Beverage | In-kind items and services | $13.11 | General |
| Category: BioOncology | ||||||
| 11/09/2018 | COMSORT, Inc | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $150.00 | General |
| Category: ONCOLOGY | ||||||
| 11/08/2018 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $120.19 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 406 | 1,444 | $207,349 | $57,098 |
| 2022 | 15 | 628 | 5,611 | $586,715 | $110,205 |
| 2021 | 11 | 607 | 3,748 | $532,984 | $120,709 |
| 2020 | 11 | 601 | 8,482 | $1.6M | $532,920 |
Total Patients
2,242
Total Services
19,285
Medicare Billing
$820,932
Procedure Codes
44
All Medicare Procedures & Services
44 procedure records from CMS Medicare Utilization — Page 2 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 204 | 271 | $39,246 | $16,462 | 41.9% |
| 96402 | Hormonal anti-neoplastic chemotherapy administration beneath the skin or into muscle | Office | 2021 | 14 | 189 | $11,340 | $4,362 | 38.5% |
| 96367 | Infusion into a vein for therapy prevention or diagnosis additional sequential infusion up to 1 hour | Office | 2021 | 13 | 171 | $10,335 | $4,190 | 40.5% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2021 | 45 | 326 | $10,941 | $2,438 | 22.3% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 13 | 13 | $4,165 | $1,483 | 35.6% |
| J3489 | Injection, zoledronic acid, 1 mg | Office | 2021 | 12 | 117 | $5,967 | $940.64 | 15.8% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2021 | 159 | 313 | $2,992 | $939.00 | 31.4% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2021 | 11 | 31 | $2,401 | $343.79 | 14.3% |
| J9355 | Injection, trastuzumab, excludes biosimilar, 10 mg | Office | 2020 | 11 | 5,619 | $1.2M | $415,559 | 34.7% |
| J9395 | Injection, fulvestrant, 25 mg | Office | 2020 | 13 | 1,480 | $280,830 | $67,330 | 24.0% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 246 | 322 | $46,632 | $16,916 | 36.3% |
| 96413 | Infusion of chemotherapy into a vein up to 1 hour | Office | 2020 | 15 | 125 | $33,850 | $12,046 | 35.6% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 69 | 147 | $31,220 | $11,776 | 37.7% |
| 96402 | Hormonal anti-neoplastic chemotherapy administration beneath the skin or into muscle | Office | 2020 | 13 | 146 | $8,760 | $3,395 | 38.8% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test | Office | 2020 | 57 | 244 | $8,189 | $1,835 | 22.4% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 12 | 12 | $3,845 | $1,427 | 37.1% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis up to 1 hour | Office | 2020 | 12 | 20 | $2,761 | $993.72 | 36.0% |
| J3489 | Injection, zoledronic acid, 1 mg | Office | 2020 | 14 | 106 | $5,406 | $862.57 | 16.0% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2020 | 139 | 261 | $2,495 | $779.52 | 31.2% |
About Dr. Saifuddin Soniwala, M.D
Dr. Saifuddin Soniwala, M.D is a Hematology & Oncology healthcare provider based in Williamsville, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/14/2006. The National Provider Identifier (NPI) number assigned to this provider is 1982620027.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Saifuddin Soniwala, M.D has received a total of $22,854 in payments from pharmaceutical and medical device companies, with $197.12 received in 2024. These payments were reported across 57 transactions from 17 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($20,000).
As a Medicare-enrolled provider, Soniwala has provided services to 2,242 Medicare beneficiaries, totaling 19,285 services with total Medicare billing of $820,932. Data is available for 4 years (2020–2023), covering 44 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Williamsville, NY
- Active Since 07/14/2006
- Last Updated 09/16/2014
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1982620027
Products in Payments
- NINLARO (Drug) $15,545
- IBRANCE (Drug) $2,902
- FASLODEX (Drug) $2,530
- KISQALI (Drug) $422.45
- KEYTRUDA (Biological) $350.00
- MYRISK (Device) $137.86
- OPDIVO (Biological) $132.62
- LYNPARZA (Drug) $125.01
- EMPLICITI (Biological) $110.00
- Perjeta (Biological) $88.06
- Enhertu (Drug) $51.56
- SARCLISA (Biological) $35.91
- FRUZAQLA (Drug) $25.92
- VENCLEXTA (Drug) $22.22
- ALUNBRIG (Drug) $20.09
- PEMAZYRE (Drug) $18.39
- BRAFTOVI (Drug) $15.80
- REBLOZYL (Biological) $14.82
- Herceptin (Biological) $13.00
- MEKINIST (Drug) $4.62
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Williamsville
Michael Krabak, Md, MD
Hematology & Oncology — Payments: $40,158
Hematology & Oncology $40,158
Hong Liu, Md Phd, MD PHD
Hematology & Oncology — Payments: $10,708
Hematology & Oncology $10,708
Dr. Robert Setlik, M.d.,Ph.d, M.D.,PH.D
Hematology & Oncology — Payments: $5,055
Hematology & Oncology $5,055
Yijun Cheng, M.d, M.D
Hematology & Oncology — Payments: $3,312
Hematology & Oncology $3,312
Frederick Hong, Md, MD
Hematology & Oncology — Payments: $1,741
Hematology & Oncology $1,741
Dr. Robert Zielinski, Md, MD
Hematology & Oncology — Payments: $289.06
Hematology & Oncology $289.06